CIDARA THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.86 USD | +12.77% |
|
-2.30% | -11.16% |
| 02:28pm | Top Premarket Gainers | MT |
| 12:07pm | North American Morning Briefing : More Tech -2- | DJ |
Presenter SpeechUnknown Executive (Executives)Good morning, and welcome to the Cidara Therapeu...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Cidara Therapeutics, Inc. is a biotechnology company. The Company is focused on the discovery, development and commercialization of therapeutics designed for patients facing serious diseases. The Company's lead product candidate is rezafungin acetate, an intravenous formulation of an echinocandin. Rezafungin is being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious invasive fungal infections. The Companyâs primary focus is using its Cloudbreak platform to develop a potential new class of drugs called drug-Fc conjugates (DFCs), for the prevention and treatment of serious diseases. This technology couplesâ potent inhibitors to a human antibody fragment to create long-acting DFCs designed to inhibit multiple disease targets. Its advanced DFC program is CD388, a long-acting antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase I and Phase IIa clinical trials.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
12.29
USD
Average target price
90
USD
Spread / Average Target
+632.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -11.16% | 56.06M | |
| -2.87% | 104B | |
| +1.16% | 97.42B | |
| +1.22% | 22.2B | |
| -18.32% | 21.23B | |
| -10.72% | 18.33B | |
| -42.33% | 16.35B | |
| -18.14% | 15.06B | |
| +5.31% | 13.98B | |
| +27.65% | 11.66B |
- Stock Market
- Equities
- CDTX Stock
- News Cidara Therapeutics, Inc.
- Transcript : Cidara Therapeutics, Inc. - Special Call
